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EDITORIAL
RDW  as  a  Surrogate  Marker  for  Active  Crohn’s  Disease:
Potential Utility
RDW  Como  Marcador  de  Atividade  na  Doenc¸a de  Crohn:
Qual  a  Potencial  Utilidade?
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hCrohn’s  disease  (CD)  is  a  chronic  and  relapsing  condition  with
the  majority  of  patients  experiencing  a  progressive  course
which  leads  to  permanent  bowel  damage.1,2 Early  control
of  inﬂammation  is  now  advocated  by  most  authors  in  order
to  prevent  permanent  bowel  damage.  Current  guidelines
for  the  management  of  CD  recommend  a  sequential  and
additive  step-care  paradigm.3--5 Salicylates  should  be  used
solely  in  mild  disease,  corticosteroids  in  the  acute  ﬂares,
while  immunosupressives  (azathioprine,  6-mercaptopurine
and  methotrexate)  are  reserved  for  patients  with  severe
disease  and/or  who  develop  corticodependency.  Currently,
both  inﬂiximab  and  adalimumab  are  approved  in  the  Euro-
pean  Union  as  second-line  treatments  for  severe,  active  CD
not  responding  or  being  intolerant  to  conventional  therapy.6
In  contrast  with  this  more  conservative  approach,  some
authors  now  propose  a  top-down  approach  where  biologics
with  or  without  immunosuppressives  would  be  started  early
in  the  course  of  disease  with  the  aim  of  avoiding  long  term
structural  damage  to  the  bowel  and  thereby  change  the  nat-
ural  history  of  disease.7DOI of original article:
http://dx.doi.org/10.1016/j.jpge.2015.10.003
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under the CC BY-NC-ND license (http://creativecommons.org/licenses/bThe  characterization  of  a  response  to  medication  has  also
volved  over  time.  In  the  past,  response  was  based  mainly  on
linical  symptoms,  with  or  without  biologic  markers,  namely
-reactive  protein  (CRP).  However,  it  has  been  recognized
hat  in  CD  there  is  a  poor  correlation  between  clinical  symp-
oms  and  the  endoscopic  status  of  the  intestinal  mucosa,
he  paradigm  being  that  most  patients  promptly  respond  to
orticosteroids  but  mucosal  healing  (MH)  is  rarely  observed
ith  these  agents.  Furthermore,  in  line  with  the  concept  of
voiding  long  term  damage,  a  strong  emphasis  has  been  put
n  MH  as  a  desirable  endpoint  since  some  studies  observed
hat  severe  endoscopic  disease  was  associated  with  a  more
ggressive  course  of  disease  and  need  for  surgery.8 As  such,
ome  authors  have  proposed  that,  even  in  clinical  practice,
H  should  become  a therapeutic  goal.9
However,  evaluation  of  mucosal  healing  in  Crohn’s  dis-
ase  implies  a total  ileo-colonoscopy  which  is  nor  practical
or  feasible  to  monitor  disease  activity  at  short  inter-
als.  To  improve  this  non-invasive  monitoring  of  disease
ctivity  in  Crohn’s  disease  several  biomarkers  such  as  cal-
rotectin  or  lactoferrin  have  been  proposed.  Still,  these
ave  not  entered  into  the  clinical  arena  in  the  sense  that
hey  are  not  ordered  on  a  routine  basis  but  mainly  when
oubts  persist  whether  the  patient  is  responding  to  a  certain
herapy.
dade Portuguesa de Gastrenterologia. This is an open access article
y-nc-nd/4.0/).
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Also,  with  the  therapeutic  treat-to-target  strategy  rec-
mmended  nowadays,  most  of  CD  patients  remain  well  for
xtended  periods  of  time.  As  they  are  often  young  people
ith  active  personal  and  professional  lives,  strategies  that
ould  allow  them  to  decrease  number  of  visits  to  the  Hos-
ital,  would  certainly  contribute  to  improve  their  quality  of
ife.
In  this  issue  of  GE,  Oliveira  et  al.10 examined  whether
ed  Cell  Distribution  Width  (RDW)  could  be  used  as  a  sur-
ogate  marker  for  disease  activity  in  CD  patients.  Red  cell
istribution  width  (RDW)  is  a  quantitative  measure  of  vari-
bility  in  the  size  of  circulating  erythrocytes.  It  is  routinely
easured  by  automated  hematology  analyzers  not  imply-
ng  additional  costs.  In  the  last  years,  numerous  studies
ave  shown  that  a  higher  RDW  is  associated  with  several
athologic  conditions,  some  suggesting  that  is  could  be
sed  an  inﬂammatory  marker  for  IBD,  mainly  in  an  inpa-
ient  setting.11,12 Although  the  mechanisms  that  mediate
he  relationship  between  high  RDW  values  and  increased  CD
ctivity  are  still  unknown,  it  has  been  demonstrated  that
 chronic  inﬂammatory  state  may  contribute  to  ineffective
rythropoiesis  causing  immature  erythrocytes  to  enter  the
irculation,  resulting  in  elevated  RDW.
The  purpose  of  this  study  was,  ﬁrstly,  to  determine
hether  RDW  was  associated  with  CDAI  and,  secondly,  to
dentify  a  possible  RDW  cutoff  with  clinical  applicability  for
n  outpatient  setting.  It  was  a  cross  sectional  study  including
19  patients  with  CD,  observed  consecutively  in  an  outpa-
ient  setting.  CD  activity  was  determined  by  CDAI  (active
isease  if  CDAI  ≥150).  The  authors  observed  an  associa-
ion  between  RDW  and  disease  activity  (p  =  0.044).  After
djustment  for  age  and  gender,  this  association  remained
onsistent  (OR  1.20,  95%  CI  1.03--1.39,  p  =  0.016).  It  was  also
ound  that  the  association  between  RDW  and  disease  activ-
ty  was  independent  of  hemoglobin  and  ESR  (OR  1.36,  95%
I  1.08--1.72,  p  =  0.01)  and  of  biologic  therapy  (OR  1.19,  95%
I  1.03--1.37,  p  =  0.017).
A  RDW  cutoff  of  16%  had  a  speciﬁcity  and  negative  pre-
ictive  value  for  CDAI  ≥150  of  88%  and  86%,  respectively.
he  authors  concluded  that  these  results  could  contribute
o  the  implementation  of  this  simple  parameter,  in  clinical
ractice,  aiming  to  help  therapeutic  decisions.
Recently  The  Selecting  Therapeutic  Targets  in  Inﬂamma-
ory  Bowel  Disease  (STRIDE)  program  was  published  with  the
im  of  identifying  potential  treatment  targets  to  be  used
or  a  ‘‘treat-to-target’’  strategy  using  an  evidence-based
xpert  consensus  process.13 In  respect  to  Crohn’s  disease
he  group  agreed  upon  clinical/patient-reported  outcome
PRO)  remission  deﬁned  as  resolution  of  abdominal  pain
nd  diarrhea/altered  bowel.  Biomarker  remission  (normal
-reactive  protein  (CRP)  and  calprotectin)  was  considered
olely  as  an  adjunctive  target.
As  we  are  now  heading  to  a  so-called  era  of  telemedicine
here  patients  are  invited  to  use  and  report  more  on
igital  platforms,  we  could  easily  conceive  the  inclusion
f  PRO  and  routine  blood  tests,  including  RDW  values,  in
 remote  monitoring  of  disease  activity  in  patients  with
D.  Telemedicine  is  used  in  many  clinical  specialities  and
cross  numerous  healthcare  settings,  which  range  from
obile  patient-centric  applications  to  complex  interactions
mongst  clinicians  in  tertiary  referral  hospital  settings.  In  a
ecently  published  paper,  Wilson  and  Maeder14 review  theM.  Cravo
ecent  directions  in  telemedicine.  They  discuss  some  recent
reas  of  signiﬁcant  development  and  progress  in  the  ﬁeld  of
elemedicine,  with  the  purpose  of  identifying  strong  trends
n  both  research  and  practice  activities.  It  is  concluded  that
wo  major  drivers  of  contemporary  telemedicine  develop-
ent  are  a high  volume  demand  for  a  particular  clinical
ervice,  and/or  a  high  criticality  of  need  for  clinical  exper-
ise  to  deliver  the  service.  These  areas  offer  promise  for
urther  study  and  enhancement  of  applicable  telemedicine
ethods  and  have  the  potential  for  large-scale  deployments
nternationally,  which  would  contribute  signiﬁcantly  to  the
dvancement  of  healthcare.
With  respect  to  inﬂammatory  bowel  disease,  we  can  say
hat  it  is  a  high  prevalent  disease,  affecting  mainly  young
eople  and,  in  the  past  decade,  treatment  of  this  disease
as  improved  tremendously,  with  most  patients  being  well
ontrolled  with  medical  therapy.  Having  said  so,  it  is  also
ecognized  that  highly  trained  specialists  in  this  area  are
ew  and  chronic  bowel  damage  occurs  in  poorly  controlled
atients.  The  latter  are  the  ones  that  physicians  want  to
etect  early  in  order  to  intensify  therapy.  We  could  then
magine  a scenario  where  most  patients  would  self  report  to
he  physician  every  3--4  months  (namely  to  detect  adverse
ffects  from  therapy  used)  and  a  visit  to  the  Hospital  with
ore  deep  evaluation  probably  including  endoscopic  eval-
ation,  would  only  occur  every  12--18  months.  Patients
eporting  ‘‘red  ﬂags’’  signs  or  symptoms  would  be  appointed
o  come  to  the  Hospital  earlier  than  planned  so  that  a  full
valuation  clariﬁes  whether  disease  is  active  or  not.
In  the  study  by  Oliveira  et  al,  RDW  values  seem  very
peciﬁc  with  a  high  negative  predictive  value  for  detec-
ing  active  Crohn’s  disease.  This  gives  some  assurance  that
e  are  not  letting  go  patients  with  active  disease.  In  con-
unction  with  patient-reported  outcome  (PRO),  RDW  value
ould  be  useful  in  identifying  patients  who  are  at  risk  of  hav-
ng  active  disease.  It  would  be  interesting  to  see  how  this
trategy  would  work  on  a  prospective  basis.
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